I don't understand why negative sentiment.
The company was never going to go into detail beyond their disclosure requirements and commercial partner arrangements.
I for one believe we have the right team in place to take us to what this company should have been/could be.
Legal experts are renegotiating the licencing rates, we have a management team with a track record and with the relevant experience, and more than a handful of products in the next 12 months going to market.
Interest from other parties relating to Bodyguard, meeting in early October - hopefully we should hear about that prior to the AGM.
Our directors paid 2.5c and 2.9c entries and have added to their positions.
Maybe biotech/pharma isn't suitable for a number of investors here? Bio is a long road and always faces hurdles, delays and obstacles.
Just look at P&G marketing, they are going all in based on the tech. This shows me that they are spending significant $$$ changing consumer behavior. I doubt they are going to turn around after convincing their customers this is revolutionary.
OBJ Price at posting:
2.1¢ Sentiment: Buy Disclosure: Held
(20min delay)